Biosimilars – and the policy and regulatory debates surrounding these complex large-molecule drugs – continue to be a hot topic in Washington. A patent case in front of the Supreme Court and laws making their way through Congress have the potential to change the market and industry.
The Atlantic will convene key stakeholders to discuss the state of and future for biosimilars. What impact will ongoing regulatory and policy considerations have? What can stakeholders expect when it comes to patents and exclusivity? And what effect will the priorities of leadership in Congress and the Administration have on the industry across the next few years?
8:00 — 10:00 am ET
Knight Broadcast Studio
555 Pennsylvania Avenue, NW
Washington, DC 20001
For more information, please contact Carly Spraggins at firstname.lastname@example.org
Also in This Series
The Next Drugs: The Future for Biosimilars
An Atlantic Policy Briefing
The Atlantic gathered key stakeholders to examine the future for biosimilars domestically and abroad.
The Next Drugs:
An Atlantic Policy Briefing on Biosimilars
The Atlantic will gather key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States.
Featuring Graham Allison
and Jeffrey Goldberg
Graham Allison, Director of Harvard University's Belfer Center for Science and International Affairs, and author of Destined for War: Can America and China Escape Thucydides’s Trap?, will join The Atlantic’s Editor in Chief Jeffrey Goldberg to explore the US-China relationship and see how war in East Asia can be avoided.